Statins fail to reduce mortality rate in sepsis patients with ARDS

May 18, 2014

Despite previously-reported observational and basic science evidence suggesting the use of statins may improve outcomes in patients with sepsis and acute respiratory distress syndrome (ARDS), a double-blinded clinical trial of rosuvastatin in those patients was futile, and the study was halted.

The findings are published in the May 18, 2014 New England Journal of Medicine, along with accompanying editorials evaluating the research's goals and outcomes. The primary investigator and lead author of the study is Jonathon D. Truwit, M.D., professor of medicine and enterprise chief medical officer and senior administrative dean at Froedtert & the Medical College of Wisconsin.

Despite improvements in supportive care for ARDS, the mortality rate remains high, one in four patients die. Sepsis is the major reason patients develop ARDS. Statins have been shown to reduce inflammation and prevent ARDS in basic science studies, and have also been reported in observational studies to improve outcomes in patients with and ARDS.

In this study, patients received either the or a placebo, and the study was double-blinded. After 745 of the proposed 1000 patients had been enrolled in the multi-center trial, the study was halted because there was no significant difference between the study groups. Further, the rosuvastatin therapy may have contributed to hepatic and renal organ dysfunction.

"While this therapy did not lead to better outcomes, it is important that we evaluate possible therapies for conditions such as ARDS because it adds to our knowledge about this condition, which has a high mortality rate for patients. The information gathered in this study will guide further basic and clinical research to ultimately improve our care for critically ill ," said Dr. Truwit.

Explore further: New tool helps doctors better predict, prevent deadly respiratory failure

Related Stories

New tool helps doctors better predict, prevent deadly respiratory failure

April 22, 2014
A new prediction tool can help doctors better identify patients who are at highest risk for respiratory failure after surgery and therefore prevent the often deadly condition, suggest data from a large multi-center study ...

International panel updates definition of acute respiratory distress syndrome

May 21, 2012
Gordon D. Rubenfeld, M.D., of the Sunnybrook Health Sciences Center, Toronto, Canada, and colleagues with the ARDS (acute respiratory distress syndrome) Definition Task Force, developed a new definition of ARDS (the Berlin ...

ATS: Early prone positioning reduces mortality in ARDS

May 21, 2013
(HealthDay)—For patients with acute respiratory distress syndrome (ARDS), prolonged prone positioning during mechanical ventilation is associated with significantly reduced mortality at 28 and 90 days, according to a study ...

Mechanical ventilation at lower level among patients without lung injury linked with better outcomes

October 23, 2012
Among patients without acute respiratory distress syndrome, protective mechanical ventilation with use of lower tidal volumes (the volume of air inhaled and exhaled during each breath) was associated with better outcomes ...

Revised ARDS definition sets out levels of severity

May 22, 2012
An international task force this week unveiled a revised definition of acute respiratory distress syndrome (ARDS), a disease first recognized during the Vietnam War in casualties with limb injuries who had trouble breathing.

Recommended for you

Co-infection with two common gut pathogens worsens malnutrition in mice

July 27, 2017
Two gut pathogens commonly found in malnourished children combine to worsen malnutrition and impair growth in laboratory mice, according to new research published in PLOS Pathogens.

Finish your antibiotics course? Maybe not, experts say

July 27, 2017
British disease experts on Thursday suggested doing away with the "incorrect" advice to always finish a course of antibiotics, saying the approach was fuelling the spread of drug resistance.

Phase 3 trial confirms superiority of tocilizumab to steroids for giant cell arteritis

July 26, 2017
A phase 3 clinical trial has confirmed that regular treatment with tocilizumab, an inhibitor of interleukin-6, successfully reduced both symptoms of and the need for high-dose steroid treatment for giant cell arteritis, the ...

A large-scale 'germ trap' solution for hospitals

July 26, 2017
When an infectious airborne illness strikes, some hospitals use negative pressure rooms to isolate and treat patients. These rooms use ventilation controls to keep germ-filled air contained rather than letting it circulate ...

Researchers report new system to study chronic hepatitis B

July 25, 2017
Scientists from Princeton University's Department of Molecular Biology have successfully tested a cell-culture system that will allow researchers to perform laboratory-based studies of long-term hepatitis B virus (HBV) infections. ...

Male hepatitis B patients suffer worse liver ailments, regardless of lifestyle

July 25, 2017
Why men with hepatitis B remain more than twice as likely to develop severe liver disease than women remains a mystery, even after a study led by a recent Drexel University graduate took lifestyle choices and environments ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.